Corient Private Wealth LLC Acquires 411,907 Shares of Novo Nordisk A/S (NYSE:NVO)

Corient Private Wealth LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 49.3% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,248,215 shares of the company's stock after acquiring an additional 411,907 shares during the quarter. Corient Private Wealth LLC's holdings in Novo Nordisk A/S were worth $129,128,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pacific Center for Financial Services lifted its stake in Novo Nordisk A/S by 100.0% during the third quarter. Pacific Center for Financial Services now owns 270 shares of the company's stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Bell Investment Advisors Inc grew its position in Novo Nordisk A/S by 79.9% during the third quarter. Bell Investment Advisors Inc now owns 286 shares of the company's stock valued at $26,000 after acquiring an additional 127 shares during the last quarter. CNB Bank purchased a new position in shares of Novo Nordisk A/S during the fourth quarter worth approximately $26,000. Tyler Stone Wealth Management boosted its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company's stock valued at $27,000 after purchasing an additional 146 shares in the last quarter. Finally, West Paces Advisors Inc. grew its holdings in shares of Novo Nordisk A/S by 100.0% during the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company's stock valued at $27,000 after purchasing an additional 150 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Trading Up 1.8 %

NVO traded up $2.33 during midday trading on Tuesday, reaching $135.24. 3,556,751 shares of the company's stock traded hands, compared to its average volume of 4,692,089. The stock has a market capitalization of $606.89 billion, a price-to-earnings ratio of 46.63, a P/E/G ratio of 1.85 and a beta of 0.43. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The firm has a fifty day moving average of $128.10 and a two-hundred day moving average of $115.94. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Cantor Fitzgerald restated an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. BMO Capital Markets began coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an "outperform" rating and a $163.00 price target on the stock. Finally, Morgan Stanley assumed coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an "overweight" rating and a $120.00 price objective for the company. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $133.60.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.